Literature DB >> 2214786

Properties of estrogen and hydroxysteroid sulphotransferases in human mammary cancer.

J B Adams1, N S Phillips.   

Abstract

Partial purification (approximately x 140-fold) of estrogen sulphotransferase (EC 2.8.2.4) in human mammary estrogen receptor positive cancer tissue was achieved by affinity chromatography on adenosine-3',5'-diphosphate-agarose. It had a Mr of approximately 70,000 by gel filtration and upon electrophoresis on concave gradient polyacrylamide gels, showed a major (Mr 70,000) and a minor (Mr 200,000) peak of activity. Kinetics of this preparation (estradiol-17 beta and estrone as substrates), and also that of hydroxysteroid sulphotransferase (EC 2.8.2.2) contained in the cytosol of human mammary cancer MCF-7 cells (5-androstene-3 beta,17 beta-diol and dehydroepiandrosterone as substrates), were compared. The enzymes showed very similar behaviour, characterized by high affinity for their steroid substrates (low nM range) and co-operativity in their binding. For hydroxysteroid sulphotransferase, the adrenal-derived estrogen 5-androstene-3 beta,17 beta-diol was the preferred substrate compared to dehydro-epiandrosterone in the 0-40 nM concentration range. Such properties of the enzymes might be designed to limit the exposure of nuclear receptor to free ligand. Alternatively, a defined subcellular location would perhaps involve the enzymes in the elimination of estrogen after processing of the ligand-bound receptor.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2214786     DOI: 10.1016/0022-4731(90)90190-4

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  2 in total

Review 1.  Enzymatic regulation of estradiol-17 beta concentrations in human breast cancer cells.

Authors:  J B Adams
Journal:  Breast Cancer Res Treat       Date:  1992-03       Impact factor: 4.872

2.  Regulation of estrogen sulfotransferase by estrogen in MCF-7 human mammary cancer cells.

Authors:  J B Adams; R Vrahimis; N Phillips
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.